Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 9/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.37 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.37 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.37 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12228315 | 0.95 | SELP (0.44) | SELPENPP2TACR1SSTR1SSTR2 | |
| SCHEMBL12228815 | 0.95 | SELP (0.48) | SELPENPP2TACR1SSTR1SSTR2 | |
| SCHEMBL12202044 | 0.92 | SELP (0.54) | SELP | |
| SCHEMBL12202058 | 0.89 | SELP (0.52) | SELP | |
| SCHEMBL12202057 | 0.89 | SELP (0.51) | SELPENPP2TACR1SSTR1SSTR2 | |
| SCHEMBL12202059 | 0.89 | SELP (0.51) | SELPENPP2TACR1SSTR1SSTR2 | |
| SCHEMBL12228123 | 0.89 | MEN1 (0.43) | SELPPLA2G4AMEN1KMT2A | |
| SCHEMBL12228120 | 0.88 | ALDH1A1 (0.39) | SELPENPP2PLA2G4ATNF | |
| SCHEMBL12202043 | 0.87 | SELP (0.52) | SELP | |
| SCHEMBL13348735 | 0.86 | SELP (0.41) | SELPENPP2TACR1TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034908-B2 | Glycolipids and synthetic method thereof as well as their synthetic intermediates, and synthetic method thereof | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20100210828-A1 | NEW GLYCOLIPIDS AND SYNTHETIC METHOD THEREOF AS WELL AS THEIR SYNTHETIC INTERMEDIATES, AND SYNTHETIC METHOD THEREOF | JAPAN AS REPRESENTED BY THE PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2010-08-19 | — | — | US | disclosed |
| US-7732583-B2 | Glycolipids and synthetic method thereof as well as their synthetic intermediates, and synthetic intermediates, and synthetic method thereof | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2010-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210828-A1 | NEW GLYCOLIPIDS AND SYNTHETIC METHOD THEREOF AS WELL AS THEIR SYNTHETIC INTERMEDIATES, AND SYNTHETIC METHOD THEREOF | SGMS1, UGCG, SGMS2 | SELP 1712/4885ENPP2 90/4885TACR1 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.